{"id":"https://openalex.org/W4361892464","doi":"https://doi.org/10.1158/1078-0432.22489631","title":"Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors","display_name":"Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors","publication_year":2023,"publication_date":"2023-04-01","ids":{"openalex":"https://openalex.org/W4361892464","doi":"https://doi.org/10.1158/1078-0432.22489631"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22489631","doi":"https://doi.org/10.1158/1078-0432.22489631","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22489631","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.22489631","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021851942","display_name":"Emerson A. Lim","orcid":"https://orcid.org/0000-0001-7269-349X","observed_orcids":["https://orcid.org/0000-0001-7269-349X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emerson A. Lim","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7269-349X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johanna C. Bendell","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9426-5891","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerald S. Falchook","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9165-2191","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Todd M. Bauer","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3078-5043","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031310463","display_name":"Charles G. Drake","orcid":"https://orcid.org/0000-0001-9610-3677","observed_orcids":["https://orcid.org/0000-0001-9610-3677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charles G. Drake","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9610-3677","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023328967","display_name":"Jennifer Hsing Choe","orcid":"https://orcid.org/0000-0002-9279-0235","observed_orcids":["https://orcid.org/0000-0002-9279-0235"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer H. Choe","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9279-0235","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020223699","display_name":"Daniel J. George","orcid":"https://orcid.org/0000-0003-1499-7203","observed_orcids":["https://orcid.org/0000-0003-1499-7203","https://orcid.org/0000-0002-0836-8542"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel J. George","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1499-7203","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006191127","display_name":"Janet L. Karlix","orcid":"https://orcid.org/0000-0001-6446-6238","observed_orcids":["https://orcid.org/0000-0001-6446-6238"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janet L. Karlix","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6446-6238","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045993166","display_name":"Susanna Varkey Ulahannan","orcid":"https://orcid.org/0000-0002-7234-2283","observed_orcids":["https://orcid.org/0000-0002-7234-2283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susanna Ulahannan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7234-2283","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044997582","display_name":"Kris F. Sachsenmeier","orcid":"https://orcid.org/0000-0002-5081-8885","observed_orcids":["https://orcid.org/0000-0002-5081-8885"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kris F. Sachsenmeier","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5081-8885","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014725720","display_name":"Deanna L. Russell","orcid":"https://orcid.org/0000-0002-9650-2309","observed_orcids":["https://orcid.org/0000-0002-9650-2309"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deanna L. Russell","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9650-2309","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025045855","display_name":"Ganesh Moorthy","orcid":"https://orcid.org/0000-0003-1637-8465","observed_orcids":["https://orcid.org/0000-0003-1637-8465"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ganesh Moorthy","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1637-8465","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033816209","display_name":"Ben S. Sidders","orcid":"https://orcid.org/0000-0003-2733-3078","observed_orcids":["https://orcid.org/0000-0003-2733-3078"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ben S. Sidders","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2733-3078","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085984233","display_name":"Elizabeth A. Pilling","orcid":"https://orcid.org/0000-0001-8239-3511","observed_orcids":["https://orcid.org/0000-0001-8239-3511"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth A. Pilling","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8239-3511","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070152907","display_name":"Huifang Chen","orcid":"https://orcid.org/0000-0002-7921-2596","observed_orcids":["https://orcid.org/0000-0002-7921-2596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huifang Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7921-2596","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076814949","display_name":"Maureen Mertens Hattersley","orcid":"https://orcid.org/0000-0003-3231-8710","observed_orcids":["https://orcid.org/0000-0003-3231-8710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maureen M. Hattersley","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3231-8710","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019353672","display_name":"Mayukh Das","orcid":"https://orcid.org/0000-0002-7384-551X","observed_orcids":["https://orcid.org/0000-0002-7384-551X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mayukh Das","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7384-551X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088647694","display_name":"Rakesh Kumar","orcid":"https://orcid.org/0000-0002-4627-3667","observed_orcids":["https://orcid.org/0000-0002-4627-3667"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rakesh Kumar","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4627-3667","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078117517","display_name":"Gayle Pageau Pouliot","orcid":"https://orcid.org/0000-0001-9730-143X","observed_orcids":["https://orcid.org/0000-0001-9730-143X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gayle P. Pouliot","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9730-143X","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish R. Patel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6836-2364","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.9496999979019165,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.9496999979019165,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.04560000076889992,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adenosine-a2a-receptor-antagonist","display_name":"adenosine A2A receptor antagonists","score":0.9850000143051147},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.8199999928474426},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6869999766349792},{"id":"https://openalex.org/keywords/adenosine","display_name":"adenosine","score":0.5249999761581421},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6169999837875366}],"concepts":[{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.9693267345428467},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5745416283607483},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47763267159461975},{"id":"https://openalex.org/C2776991684","wikidata":"https://www.wikidata.org/wiki/Q190012","display_name":"Adenosine","level":2,"score":0.47548186779022217},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.4286201298236847},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41168057918548584},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3834444582462311},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3509503901004791},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.32765406370162964},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.2977631986141205},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.18138694763183594},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1349499523639679},{"id":"https://openalex.org/C124101348","wikidata":"https://www.wikidata.org/wiki/Q172491","display_name":"Data mining","level":1,"score":0.11271792650222778},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.08503708243370056},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.22489631","doi":"https://doi.org/10.1158/1078-0432.22489631","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22489631","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22489631","doi":"https://doi.org/10.1158/1078-0432.22489631","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22489631","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361958172","https://openalex.org/W4293788415","https://openalex.org/W3031067760","https://openalex.org/W2955376170","https://openalex.org/W4239473655","https://openalex.org/W4232345846","https://openalex.org/W2896523388","https://openalex.org/W3134422943","https://openalex.org/W2886880700","https://openalex.org/W4237247323"],"abstract_inverted_index":{"Supplementary":[0],"Table":[1],"from":[2],"Phase":[3],"Ia/b,":[4],"Open-Label,":[5],"Multicenter":[6],"Study":[7],"of":[8],"AZD4635":[9],"(an":[10],"Adenosine":[11],"A2A":[12],"Receptor":[13],"Antagonist)":[14],"as":[15],"Monotherapy":[16],"or":[17],"Combined":[18],"with":[19,23],"Durvalumab,":[20],"in":[21],"Patients":[22],"Solid":[24],"Tumors":[25]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}